Analytical Data
-
Gene name
RANTES/CCL5
- Application
-
Alternative Names
CCL5; SCYA5; SISd; EoCP; Chemokine C-C-Motif Ligand 5; Eosinophil Chemotactic Cytokine; T-cell Specific Protein p288; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 5
-
Species
Pig
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q2EN89
-
Expression Region
Ser24~Ser91
-
Protein Length
Partial
-
Molecular Weight
12kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RANTES, also known as CCL5 (Regulated upon Activation, Normal T cell Expressed and Secreted), is a crucial chemokine involved in the immune response and inflammation. It primarily functions as a chemoattractant for various immune cells, including T cells, eosinophils, and basophils, influencing their migration and activation during inflammatory and immune reactions. Research into RANTES/CCL5 has gained significant attention due to its role in various pathological conditions, including viral infections, autoimmune diseases, and cancer metastasis. The recombinant production of RANTES/CCL5 has enabled scientists to explore its biological functions, investigate therapeutic applications, and develop potential pharmaceuticals to modulate immune responses. By using techniques such as genetic engineering and protein expression systems, researchers can produce large quantities of this chemokine for detailed studies. These investigations have revealed RANTES/CCL5’s involvement in T cell polarization, its impact on the tissue microenvironment, and its potential as a biomarker for disease progression. Furthermore, understanding the signaling pathways and receptor interactions of RANTES/CCL5 has opened up new avenues for therapeutic interventions in inflammatory diseases and cancer treatment, highlighting its significance as a target in immunotherapy. Consequently, the study of RANTES/CCL5 recombinant protein continues to be a vibrant area of research, promising advancements in both basic biology and clinical applications.
